Related references
Note: Only part of the references are listed.Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
Dandan Li et al.
ADVANCES IN THERAPY (2022)
Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations
Franziska Kluwe et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
Changqing Li et al.
BMC NEUROLOGY (2021)
From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotic
Sebastian G. Wicha et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Mycophenolic Acid Exposure Prediction Using Machine Learning
Jean-Baptiste Woillard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Incidence and predictors of serious bleeding during long-term follow-up after acute coronary syndrome in a population-based cohort study
Anna Graipe et al.
SCIENTIFIC REPORTS (2021)
Machine Learning as a Novel Method to Support Therapeutic Drug Management and Precision Dosing
Teun van Gelder et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation
Tom C. Zwart et al.
DRUG DISCOVERY TODAY (2021)
Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy
Joshua C. Euteneuer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management A Randomized Clinical Trial
Duk-Woo Park et al.
CIRCULATION (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects
Shuaibing Liu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians?
Doreen Tan Su-Yin
EUROPEAN CARDIOLOGY REVIEW (2018)
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
Daniel Roshammar et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2017)
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Victor L. Serebruany et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes
Jianguo Li et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2016)
Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome - Randomized, Double-Blind, Phase III PHILO Study -
Shinya Goto et al.
CIRCULATION JOURNAL (2015)
Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy
Neha Quatromoni et al.
CURRENT ATHEROSCLEROSIS REPORTS (2015)
Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers
Renli Teng et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2014)
East Asian Paradox: Challenge for the Current Antiplatelet Strategy of One-Guideline-Fits-All Races in Acute Coronary Syndrome
Young-Hoon Jeong
CURRENT CARDIOLOGY REPORTS (2014)
World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI
Glenn N. Levine et al.
GLOBAL HEART (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals
Renli Teng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment
Kathleen Butler et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James et al.
AMERICAN HEART JOURNAL (2009)
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation
J. J. J. van Giezen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
From ATP to AZD6140:: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
Brian Springthorpe et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)